Hangzhou Tigermed Consulting Co Stock | 300347.SZ | CNE100001KV8 |

Date	Hangzhou Tigermed Consulting Co Price
10/30/2024	63.97 undefined
10/29/2024	68.92 undefined
10/28/2024	71.72 undefined
10/25/2024	71.06 undefined
10/24/2024	66.73 undefined
10/23/2024	67.24 undefined
10/22/2024	67.91 undefined
10/21/2024	65.91 undefined
10/18/2024	64.00 undefined
10/17/2024	59.72 undefined
10/16/2024	60.01 undefined
10/15/2024	61.38 undefined
10/14/2024	63.82 undefined
10/11/2024	63.02 undefined
10/10/2024	67.04 undefined
10/9/2024	67.83 undefined
10/8/2024	79.22 undefined

Date	Hangzhou Tigermed Consulting Co Revenue	Hangzhou Tigermed Consulting Co EBIT	Hangzhou Tigermed Consulting Co Net Income
2026e	9.89 B undefined	2.58 B undefined	1.88 B undefined
2025e	8.7 B undefined	2.25 B undefined	1.62 B undefined
2024e	7.55 B undefined	1.85 B undefined	1.37 B undefined
2023	7.38 B undefined	1.71 B undefined	2.02 B undefined
2022	7.09 B undefined	1.78 B undefined	2.01 B undefined
2021	5.21 B undefined	1.43 B undefined	2.87 B undefined
2020	3.19 B undefined	956.7 M undefined	1.75 B undefined
2019	2.8 B undefined	802.8 M undefined	841.6 M undefined
2018	2.3 B undefined	628 M undefined	472.2 M undefined
2017	1.69 B undefined	423.6 M undefined	301 M undefined
2016	1.17 B undefined	167.5 M undefined	140.7 M undefined
2015	957 M undefined	210.9 M undefined	156.3 M undefined
2014	624.6 M undefined	153.8 M undefined	125.5 M undefined
2013	336.5 M undefined	89 M undefined	94.1 M undefined
2012	254.3 M undefined	66.7 M undefined	67.7 M undefined
2011	193.3 M undefined	54 M undefined	47.8 M undefined
2010	122.8 M undefined	34.5 M undefined	31.7 M undefined
2009	62.8 M undefined	7.1 M undefined	7.8 M undefined

	Revenue	EBIT	Net Income
2009	62.8 M CNY	7.1 M CNY	7.8 M CNY
2010	122.8 M CNY	34.5 M CNY	31.7 M CNY
2011	193.3 M CNY	54 M CNY	47.8 M CNY
2012	254.3 M CNY	66.7 M CNY	67.7 M CNY
2013	336.5 M CNY	89 M CNY	94.1 M CNY
2014	624.6 M CNY	153.8 M CNY	125.5 M CNY
2015	957 M CNY	210.9 M CNY	156.3 M CNY
2016	1.17 B CNY	167.5 M CNY	140.7 M CNY
2017	1.69 B CNY	423.6 M CNY	301 M CNY
2018	2.3 B CNY	628 M CNY	472.2 M CNY
2019	2.8 B CNY	802.8 M CNY	841.6 M CNY
2020	3.19 B CNY	956.7 M CNY	1.75 B CNY
2021	5.21 B CNY	1.43 B CNY	2.87 B CNY
2022	7.09 B CNY	1.78 B CNY	2.01 B CNY
2023	7.38 B CNY	1.71 B CNY	2.02 B CNY
2024e	7.55 B CNY	1.85 B CNY	1.37 B CNY
2025e	8.7 B CNY	2.25 B CNY	1.62 B CNY
2026e	9.89 B CNY	2.58 B CNY	1.88 B CNY

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
0.06	0.12	0.19	0.25	0.34	0.62	0.96	1.17	1.69	2.3	2.8	3.19	5.21	7.09	7.38	7.55	8.7	9.89
-	96.77	58.20	31.61	32.28	85.71	53.37	22.68	43.70	36.34	21.87	13.88	63.31	35.91	4.22	2.25	15.22	13.66
33.87	45.90	45.08	46.06	44.94	47.28	44.10	37.99	42.92	43.09	46.45	47.43	43.54	39.63	38.53	-	-	-
0.02	0.06	0.09	0.12	0.15	0.3	0.42	0.45	0.72	0.99	1.3	1.51	2.27	2.81	2.85	0	0	0
0.01	0.03	0.05	0.07	0.09	0.15	0.21	0.17	0.42	0.63	0.8	0.96	1.43	1.78	1.71	1.85	2.25	2.58
11.29	27.87	27.98	25.98	26.49	24.52	21.94	14.22	25.07	27.30	28.61	29.95	27.41	25.11	23.19	24.45	25.90	26.07
0.01	0.03	0.05	0.07	0.09	0.13	0.16	0.14	0.3	0.47	0.84	1.75	2.87	2.01	2.02	1.37	1.62	1.88
-	342.86	51.61	42.55	40.30	32.98	24.80	-10.26	115.00	56.81	78.18	107.97	64.32	-30.20	0.90	-32.46	18.22	16.46
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
405.2	473	480	533.6	640.8	638.1	650	703.3	750.3	750.3	744.8	799	870.96	864.89	865.32	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2021	2022	2023

0.02	0.04	0.09	0.56	0.53	0.45	0.24	0.54	0.61	0.7	2.11	9.99	8.57	8.41	7.81	7.48
0.02	0.02	0.05	0.09	0.13	0.3	0.38	0.45	0.63	0.78	1.16	1.32	2.1	2.09	3.03	3.63
1	2	5	8	10	10	42	72	67	58	64	119	75.85	82.78	98.29	109.23
0	0	0	0	0	0	0	0	0	1	1	5	6.1	6.1	22.2	23.4
1	21	8	4	8	21	23	36	34	64	41	220	94.79	260.73	153.97	103.3
0.04	0.09	0.14	0.66	0.68	0.79	0.69	1.09	1.35	1.6	3.37	11.65	10.85	10.85	11.11	11.34
0.02	0.02	0.02	0.05	0.08	0.15	0.19	0.2	0.2	0.26	0.43	0.68	1.12	1.14	1.34	1.49
0	0	0	0	0.02	0.05	0.19	0.46	0.88	1.33	2.36	5.37	9.5	9.5	11.8	13.22
0	0	0	0	0	0	0	0	0	0	0	0	75.85	0	0	0
0	0	8	9	10	19	14	13	17	28	96	142	250.64	250.64	338.12	371.13
0.01	0.01	0.01	0.01	0.02	0.34	0.47	0.6	1.05	1.03	1.16	1.45	1.78	1.78	2.49	2.76
0	1	3	2	2	15	50	17	87	36	122	223	219	219	380.99	492.47
0.03	0.03	0.04	0.07	0.13	0.57	0.92	1.29	2.24	2.68	4.16	7.86	12.95	12.89	16.34	18.34
0.07	0.12	0.19	0.73	0.81	1.36	1.61	2.39	3.58	4.28	7.53	19.51	23.8	23.74	27.45	29.68

30	40	40	53	107	215	433	475	500	500	750	872	872.44	872.44	872.42	872.42
0.01	0.03	0.03	0.49	0.44	0.38	0.18	0.67	1.27	1.32	1.71	12	11.89	11.89	11.85	11.71
0	0.03	0.08	0.14	0.19	0.28	0.39	0.48	0.72	1.1	1.94	3.48	6.09	6.09	7.66	9.21
0	0	0	0	0	-0.01	-0	0	-0	-0	0.03	-0.09	2.33	-0.16	0.06	0.09
0	0	0	0	0	0	0	0	0	0	0	0	0	0	8.88	8.83
0.04	0.09	0.14	0.69	0.74	0.86	1	1.63	2.49	2.92	4.42	16.25	21.17	18.69	20.45	21.9
0	0	2	12	14	17	10	15	24	44	75	101	147.87	125.75	157.96	249.31
0	1	3	6	8	22	27	43	55	89	156	183	350.68	350.68	403.5	461.53
0.02	0.02	0.03	0.02	0.03	0.08	0.18	0.2	0.32	0.41	0.63	0.78	1.35	1.33	1.15	0.91
0	0	0	0	0	0.27	0.26	0.18	0.27	0.64	0.89	0.02	0.49	0.53	1.88	1.99
0	0	0	0	0	0	0	0	63	29	33	52	74.52	74.52	137.32	519.57
0.02	0.02	0.04	0.04	0.05	0.39	0.47	0.44	0.73	1.21	1.79	1.14	2.41	2.41	3.73	4.14
0	0	0	0	0	7	24	33	32	19	154	279	406.84	406.84	733.62	857.33
0	0	0	0	0	4	9	17	13	14	46	132	201.54	201.54	214.39	213.98
0	1	3	0	0	43	40	64	4	4	20	97	-3,351.33	114.88	87.9	17.13
0	0	0	0	0	0.05	0.07	0.11	0.05	0.04	0.22	0.51	-2.74	0.72	1.04	1.09
0.02	0.02	0.04	0.04	0.05	0.44	0.54	0.55	0.78	1.25	2.01	1.65	-0.33	3.14	4.77	5.23
0.07	0.12	0.18	0.73	0.8	1.3	1.55	2.18	3.27	4.16	6.43	17.9	20.84	21.83	25.22	27.12

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2021	2022
0	0	0	0	0	0	0	0	0	0	0	0	2.87	0	0
0	0	0	0	0	0	0	0	0	0	0	0	188	0	329
0	0	0	0	0	0	0	0	0	0	0	0	0	0	-7
3	-10	-16	-93	-104	-238	-462	-552	-671	-921	-1,157	-1,314	-98	-1,734	-2,420
0	0	0	0	0	0	0	0	0	0	0	0	-1,548	0	-285
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-3	-4	-15	-17	-26	-41	-59	-71	-127	-140	-234	-241	-321	-321	-594
0.02	0.03	0.04	0.02	0.08	0.04	0.19	0.19	0.32	0.52	0.53	1	1.42	1.42	1.36
-13	-8	-16	-21	-37	-38	-87	-61	-46	-91	-102	-156	-368	-368	-448
-34	-20	4	-22	-139	-219	-413	-530	-846	-366	-638	-2,367	-2,782	-2,782	-2,789
-20	-12	20	-1	-102	-181	-326	-468	-800	-274	-535	-2,210	-2,414	-2,414	-2,340
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0.23	-0.01	-0.05	0.08	0.34	0.18	-0.9	0.4	0.49	1.61
0	0	0	0	0	0	0	0	0	0	0	0	-227	0	-87
0	0.02	0	0.48	-0.04	0.12	0.01	0.49	0.7	0.01	1.43	9.34	-0.16	-0.16	0.81
0	0.02	0	0.48	0	-0.06	0.07	0.59	0.69	-0.2	1.52	10.51	-0.05	-0.37	-0.31
0	0	0	0	-43	-46	-46	-59	-62	-126	-266	-271	-284	-284	-491
0.01	0.07	0.11	0.6	0.1	0.27	0.51	0.98	1.28	1.76	3.26	10.48	1.95	1.9	3.78
8	18.3	22.5	-6.7	39.7	5.6	98.6	130.2	269	430.5	424.7	842.2	1,055.18	1,055.18	908.9
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Hangzhou Tigermed Consulting Co Gross margin	Hangzhou Tigermed Consulting Co Profit margin	Hangzhou Tigermed Consulting Co EBIT margin	Hangzhou Tigermed Consulting Co Profit margin
2026e	38.53 %	26.07 %	19.04 %
2025e	38.53 %	25.9 %	18.59 %
2024e	38.53 %	24.45 %	18.11 %
2023	38.53 %	23.2 %	27.42 %
2022	39.64 %	25.12 %	28.32 %
2021	43.55 %	27.42 %	55.13 %
2020	47.43 %	29.97 %	54.81 %
2019	46.48 %	28.64 %	30.02 %
2018	43.1 %	27.3 %	20.52 %
2017	42.94 %	25.11 %	17.84 %
2016	38.03 %	14.26 %	11.98 %
2015	44.12 %	22.04 %	16.33 %
2014	47.33 %	24.62 %	20.09 %
2013	45.05 %	26.45 %	27.96 %
2012	46.24 %	26.23 %	26.62 %
2011	45.11 %	27.94 %	24.73 %
2010	45.6 %	28.09 %	25.81 %
2009	34.39 %	11.31 %	12.42 %

	Gross margin	EBIT margin	Profit margin
2009	34.39 %	11.31 %	12.42 %
2010	45.6 %	28.09 %	25.81 %
2011	45.11 %	27.94 %	24.73 %
2012	46.24 %	26.23 %	26.62 %
2013	45.05 %	26.45 %	27.96 %
2014	47.33 %	24.62 %	20.09 %
2015	44.12 %	22.04 %	16.33 %
2016	38.03 %	14.26 %	11.98 %
2017	42.94 %	25.11 %	17.84 %
2018	43.1 %	27.3 %	20.52 %
2019	46.48 %	28.64 %	30.02 %
2020	47.43 %	29.97 %	54.81 %
2021	43.55 %	27.42 %	55.13 %
2022	39.64 %	25.12 %	28.32 %
2023	38.53 %	23.2 %	27.42 %
2024e	38.53 %	24.45 %	18.11 %
2025e	38.53 %	25.9 %	18.59 %
2026e	38.53 %	26.07 %	19.04 %

Date	Hangzhou Tigermed Consulting Co Sales per Share	Hangzhou Tigermed Consulting Co EBIT per share	Hangzhou Tigermed Consulting Co Earnings per Share
2026e	17.54 undefined	0 undefined	3.34 undefined
2025e	15.43 undefined	0 undefined	2.87 undefined
2024e	13.39 undefined	0 undefined	2.43 undefined
2023	8.53 undefined	1.98 undefined	2.34 undefined
2022	8.19 undefined	2.06 undefined	2.32 undefined
2021	5.99 undefined	1.64 undefined	3.3 undefined
2020	4 undefined	1.2 undefined	2.19 undefined
2019	3.76 undefined	1.08 undefined	1.13 undefined
2018	3.07 undefined	0.84 undefined	0.63 undefined
2017	2.25 undefined	0.56 undefined	0.4 undefined
2016	1.67 undefined	0.24 undefined	0.2 undefined
2015	1.47 undefined	0.32 undefined	0.24 undefined
2014	0.98 undefined	0.24 undefined	0.2 undefined
2013	0.53 undefined	0.14 undefined	0.15 undefined
2012	0.48 undefined	0.13 undefined	0.13 undefined
2011	0.4 undefined	0.11 undefined	0.1 undefined
2010	0.26 undefined	0.07 undefined	0.07 undefined
2009	0.15 undefined	0.02 undefined	0.02 undefined

	Sales per Share	EBIT per share	Earnings per Share
2009	0.15 CNY	0.02 CNY	0.02 CNY
2010	0.26 CNY	0.07 CNY	0.07 CNY
2011	0.4 CNY	0.11 CNY	0.1 CNY
2012	0.48 CNY	0.13 CNY	0.13 CNY
2013	0.53 CNY	0.14 CNY	0.15 CNY
2014	0.98 CNY	0.24 CNY	0.2 CNY
2015	1.47 CNY	0.32 CNY	0.24 CNY
2016	1.67 CNY	0.24 CNY	0.2 CNY
2017	2.25 CNY	0.56 CNY	0.4 CNY
2018	3.07 CNY	0.84 CNY	0.63 CNY
2019	3.76 CNY	1.08 CNY	1.13 CNY
2020	4 CNY	1.2 CNY	2.19 CNY
2021	5.99 CNY	1.64 CNY	3.3 CNY
2022	8.19 CNY	2.06 CNY	2.32 CNY
2023	8.53 CNY	1.98 CNY	2.34 CNY
2024e	13.39 CNY	0 CNY	2.43 CNY
2025e	15.43 CNY	0 CNY	2.87 CNY
2026e	17.54 CNY	0 CNY	3.34 CNY

	Number of stocks
2009	405.2 M Aktien
2010	473 M Aktien
2011	480 M Aktien
2012	533.6 M Aktien
2013	640.8 M Aktien
2014	638.1 M Aktien
2015	650 M Aktien
2016	703.3 M Aktien
2017	750.3 M Aktien
2018	750.3 M Aktien
2019	744.8 M Aktien
2020	799 M Aktien
2021	870.96 M Aktien
2022	864.89 M Aktien
2023	865.32 M Aktien
2024e	865.32 M Aktien
2025e	865.32 M Aktien
2026e	865.32 M Aktien

Date	Hangzhou Tigermed Consulting Co Dividend
2026e	0.6 undefined
2025e	0.6 undefined
2024e	0.6 undefined
2023	0.55 undefined
2022	0.5 undefined
2021	0.3 undefined
2020	0.28 undefined
2019	0.23 undefined
2018	0.13 undefined
2017	0.07 undefined
2016	0.07 undefined
2015	0.07 undefined
2014	0.07 undefined
2013	0.07 undefined

	Dividend	Dividend (Estimate)
2009	0 CNY	0 CNY
2010	0 CNY	0 CNY
2011	0 CNY	0 CNY
2012	0 CNY	0 CNY
2013	0.07 CNY	0 CNY
2014	0.07 CNY	0 CNY
2015	0.07 CNY	0 CNY
2016	0.07 CNY	0 CNY
2017	0.07 CNY	0 CNY
2018	0.13 CNY	0 CNY
2019	0.23 CNY	0 CNY
2020	0.28 CNY	0 CNY
2021	0.3 CNY	0 CNY
2022	0.5 CNY	0 CNY
2023	0.55 CNY	0 CNY
2024e	0 CNY	0.6 CNY
2025e	0 CNY	0.6 CNY
2026e	0 CNY	0.6 CNY

Date	Hangzhou Tigermed Consulting Co Payout ratio
2026e	15.49 %
2025e	17.01 %
2024e	15.03 %
2023	14.45 %
2022	21.55 %
2021	9.09 %
2020	12.69 %
2019	20.65 %
2018	21.16 %
2017	16.67 %
2016	33.33 %
2015	27.78 %
2014	33.33 %
2013	44.44 %
2012	14.45 %
2011	14.45 %
2010	14.45 %
2009	14.45 %

	Payout ratio
2009	14.45 %
2010	14.45 %
2011	14.45 %
2012	14.45 %
2013	44.44 %
2014	33.33 %
2015	27.78 %
2016	33.33 %
2017	16.67 %
2018	21.16 %
2019	20.65 %
2020	12.69 %
2021	9.09 %
2022	21.55 %
2023	14.45 %
2024e	15.03 %
2025e	17.01 %
2026e	15.49 %

Date	EPS Estimate	EPS Actual	Quarterly report
6/30/2024	0.5	0.3 (-40 %)	2024 Q2
3/31/2024	0.54	0.27 (-49.66 %)	2024 Q1
12/31/2023	0.46	0.17 (-63.33 %)	2023 Q4
9/30/2023	0.75	0.57 (-24.4 %)	2023 Q3
6/30/2023	0.66	0.95 (44.11 %)	2023 Q2
3/31/2023	0.62	0.66 (6.43 %)	2023 Q1
12/31/2022	0.63	0.46 (-26.46 %)	2022 Q4
9/30/2022	0.67	0.48 (-28.39 %)	2022 Q3
6/30/2022	0.65	0.78 (20.23 %)	2022 Q2
3/31/2022	0.63	0.6 (-5.05 %)	2022 Q1
12/31/2021	0.45	1.27 (181.28 %)	2021 Q4
9/30/2021	0.41	0.61 (48.94 %)	2021 Q3
6/30/2021	0.55	0.92 (68.68 %)	2021 Q2
3/31/2021	0.39	0.52 (32.01 %)	2021 Q1
12/31/2020	0.18	0.49 (166.89 %)	2020 Q4
9/30/2020	0.35	0.39 (11.62 %)	2020 Q3
6/30/2020	0.28	0.99 (257.45 %)	2020 Q2
3/31/2020	0.28	0.34 (21.02 %)	2020 Q1
12/31/2019	0.33	0.43 (27.78 %)	2019 Q4
9/30/2019	0.22	0.23 (6.48 %)	2019 Q3
6/30/2019	0.26	0.28 (5.5 %)	2019 Q2
3/31/2019	0.19	0.19 (-0.31 %)	2019 Q1
12/31/2018	0.18	0.21 (14.65 %)	2018 Q4
9/30/2018	0.16	0.13 (-19.47 %)	2018 Q3
6/30/2018	0.16	0.16 (3.81 %)	2018 Q2
3/31/2018	0.12	0.13 (5.47 %)	2018 Q1
12/31/2017	0.14	0.13 (-5.23 %)	2017 Q4

%	Name	Stocks	Change	Date
31.44051 %	Ye (Xiaoping)	177,239,541	0	12/31/2023
9.16428 %	Cao (Xiaochun)	51,661,774	0	12/31/2023
5.39658 %	Zhong Ou Asset Management Co., Ltd.	30,422,105	-14,368,400	12/31/2023
4.63436 %	Bank of Communications Schroder Fund Management Co., Ltd.	26,125,259	-15,100	12/31/2023
3.86367 %	E Fund Management Co. Ltd.	21,780,670	821,200	12/31/2023
2.50445 %	Hwabao WP Fund Management Co., Ltd.	14,118,309	-2,081,100	12/31/2023
2.20133 %	Temasek Fullerton Alpha Pte. Ltd.	12,409,532	-6,681,467	12/31/2023
2.01711 %	INVESCO Great Wall Fund Management Co. Ltd.	11,371,023	3,382,548	12/31/2023
1.89420 %	Shi (Xiao Li)	10,678,175	0	12/31/2023
1.81293 %	Zhuan (Yin)	10,220,000	0	12/31/2023
1.76716 %	China Merchants Fund Management Co. Ltd.	9,962,011	-487,879	12/31/2023
1.34223 %	HuaAn Fund Management Co., Ltd.	7,566,557	47,000	12/31/2023
1.32890 %	Federated Hermes International	7,491,394	1,511,094	2/29/2024
1.09825 %	GF Fund Management Co., Ltd.	6,191,174	1,535,900	12/31/2023
0.99238 %	China Universal Asset Management Co., Ltd.	5,594,332	-322,011	12/31/2023
0.98100 %	abrdn Asia Limited	5,530,194	-331,900	2/29/2024
0.96708 %	Tianhong Asset Management Co., Ltd.	5,451,728	4,200	12/31/2023
0.91906 %	Schroder Investment Management (Hong Kong) Ltd.	5,181,026	0	12/31/2023
0.90495 %	UBS Asset Management (Hong Kong) Limited	5,101,477	0	12/31/2023
0.79057 %	Harvest Fund Management Co., Ltd.	4,456,672	0	2/29/2024
0.78348 %	Yinhua Fund Management Co., Ltd.	4,416,734	63,200	12/31/2023
0.73362 %	Huatai-PineBridge Fund Management Co., Ltd.	4,135,631	2,002,693	12/31/2023
0.69285 %	JPMorgan Asset Management (Asia Pacific) Limited	3,905,777	0	3/31/2024
0.68975 %	Morgan Stanley Investment Management (China) Company Limited.	3,888,305	-754,877	12/31/2023
0.63437 %	J.P. Morgan Asset Management (Singapore) Limited	3,576,156	-584,100	8/31/2022
0.53776 %	China Southern Asset Management Co. Ltd.	3,031,505	-270,570	12/31/2023
0.50935 %	Fullgoal Fund Management Co., Ltd.	2,871,334	-209,400	12/31/2023
0.50913 %	China Asset Management Co., Ltd.	2,870,130	504,467	12/31/2023
0.39240 %	Galaxy Asset Management Co., Ltd.	2,212,059	283,000	12/31/2023
0.36751 %	The Vanguard Group, Inc.	2,071,736	-81,400	3/31/2024
0.36223 %	Ping An Fund Management Company Limited	2,042,000	0	12/31/2023
0.34611 %	Guotai Asset Management Co., Ltd.	1,951,149	-11,200	12/31/2023
0.26721 %	APG Asset Management N.V.	1,506,364	-471	9/30/2023
0.21272 %	Norges Bank Investment Management (NBIM)	1,199,167	-624,672	12/31/2023
0.20718 %	China Fund Management Co., Ltd.	1,167,940	17,900	12/31/2023
0.20244 %	Allianz Global Investors Singapore Ltd.	1,141,206	-6,136,795	1/31/2023
0.18343 %	Grandeur Peak Global Advisors, LLC	1,034,068	-68,100	1/31/2024
0.18170 %	ICBC Credit Suisse Asset Management Co. Ltd.	1,024,300	-400	12/31/2023
0.15515 %	UBS Asset Management (UK) Ltd.	874,648	500	3/31/2024
0.15253 %	Rongtong Fund Management Co., Ltd.	859,866	2,200	12/31/2023
0.13880 %	Wanjia Asset Management Co., Ltd.	782,480	695,680	6/30/2023
0.12783 %	Great Wall Fund Management Co., Ltd.	720,594	-1,209,441	6/30/2023
0.12504 %	Bosera Asset Management Co., Ltd.	704,910	154,400	12/31/2023
0.12265 %	Invesco Advisers, Inc.	691,390	0	10/31/2022
0.09733 %	UBS Asset Management (Switzerland)	548,674	0	2/29/2024
0.09531 %	Fidelity Management & Research (Hong Kong) Limited	537,305	-43,400	2/29/2024
0.09351 %	BlackRock Institutional Trust Company, N.A.	527,141	25,900	3/31/2024
0.08492 %	PengYang Asset Management Co., Ltd	478,693	-30,800	6/30/2023
0.08019 %	Harvest Global Investments Limited	452,032	0	3/31/2024
0.07840 %	Dacheng Fund Management Co., Ltd.	441,990	200	12/31/2023
0.07819 %	Cinda Fund Management Co., Ltd.	440,762	440,762	12/31/2023
0.07710 %	BlackRock Advisors (UK) Limited	434,621	16,100	3/31/2024
0.07027 %	Penghua Fund Management Co., Ltd.	396,146	190,467	6/30/2023
0.06785 %	Principal Global Investors (Hong Kong) Limited	382,500	382,500	12/31/2022
0.06258 %	China Asset Management (Hong Kong) Limited	352,789	26,200	3/31/2024
0.05627 %	Wasatch Global Investors Inc	317,238	-26,700	12/31/2023
0.05357 %	Orient Securities Asset Management Company Limited	302,000	-10,417	6/30/2023
0.04856 %	California State Teachers Retirement System	273,731	-120,155	6/30/2023
0.04816 %	DWS Investments UK Limited	271,510	-647	3/31/2024
0.04693 %	State Street Global Advisors (US)	264,539	-5,000	3/31/2024
0.04683 %	Truvalue Asset Management Co., Ltd.	264,000	-757,671	6/30/2023
0.04305 %	Amundi Asset Management, SAS	242,672	55,600	3/31/2024
0.04169 %	Huashang Fund Management Co., Ltd.	235,000	41,300	12/31/2023
0.04155 %	Capital Investment Trust Corporation	234,244	234,244	12/31/2023
0.04089 %	Guotai Junan Securities Assets Management Co., Ltd.	230,500	133,600	6/30/2023
0.03258 %	Mellon Investments Corporation	183,667	-5,800	3/31/2024
0.03008 %	Lion Fund Management Co., Ltd.	169,594	96,000	12/31/2023
0.02999 %	Matthews International Capital Management, L.L.C.	169,076	0	2/29/2024
0.02939 %	SEB Asset Management (Denmark)	165,678	-168,003	2/29/2024
0.02515 %	Mirae Asset Global Investments Co., Ltd.	141,758	138	1/31/2024
0.02489 %	Taikang Asset Management Co., Ltd.	140,307	-4,300	6/30/2023
0.02444 %	Degroof Petercam Asset Management	137,756	-12,109	12/31/2023
0.02409 %	Tibet Eastmoney Fund Management Co., Ltd.	135,800	-10,700	12/31/2023
0.02350 %	Western Leadbank Fund Management Co., Ltd.	132,459	68,000	6/30/2023
0.02340 %	BlackRock (Singapore) Limited	131,927	29,022	3/31/2024
0.02335 %	China Life AMP Asset Management Co., Ltd	131,609	4,300	12/31/2023
0.02180 %	CITIC Prudential Fund Management Co., Ltd.	122,900	2,000	6/30/2023
0.02155 %	Beixin Ruifeng Fund Management Co., Ltd.	121,500	23,500	12/31/2023
0.01964 %	JT Asset Management Co., Ltd.	110,700	-16,600	6/30/2023
0.01932 %	JPMorgan Asset Management (China) Company Limited.	108,900	8,000	6/30/2023
0.01749 %	Taiping Fund Management Co., Ltd.	98,600	98,600	6/30/2023
0.01689 %	Everbright PGIM Fund Management Co., Ltd.	95,225	-13,400	12/31/2023
0.01614 %	CCB Principal Asset Management Co., Ltd.	91,008	-1,300	12/31/2023
0.01598 %	JPMorgan Asset Management U.K. Limited	90,102	1,000	3/31/2024
0.01559 %	BlackRock Investment Management, LLC	87,900	-2,200	12/31/2023
0.01548 %	SWS MU Fund Management Co., Ltd.	87,291	-8,400	6/30/2023
0.01517 %	Maxwealth Fund Management Co., Ltd.	85,532	20,100	6/30/2023
0.01506 %	Founder Fubon Fund Management Co., Ltd.	84,900	-600	12/31/2023
0.01501 %	Xingyin Fund Management Co., Ltd.	84,600	-5,900	6/30/2023
0.01477 %	Geode Capital Management, L.L.C.	83,257	6,500	2/29/2024
0.01252 %	Amundi Japan Ltd.	70,600	8,200	3/31/2024
0.01249 %	Nikko Asset Management Asia Limited	70,394	-249,892	11/30/2023
0.01241 %	Union Investment Privatfonds GmbH	69,941	-419,964	6/30/2023
0.01227 %	Ninety One North America, Inc.	69,156	0	12/31/2023
0.01169 %	State Street Global Advisors (UK) Ltd.	65,883	0	3/31/2024
0.01160 %	CPIC Fund Management Co., Ltd.	65,398	-2,900	12/31/2023
0.01148 %	Charles Schwab Investment Management, Inc.	64,700	0	3/31/2024
0.00995 %	Xinjiang Qianhai Alliance Asset Management Co., Ltd.	56,100	-60,400	6/30/2023
0.00969 %	Purekind Fund Management Co., Ltd.	54,600	-70,400	6/30/2023
0.00965 %	CSOP Asset Management Limited	54,400	0	3/31/2024

What values and corporate philosophy does Hangzhou Tigermed Consulting Co represent?

Hangzhou Tigermed Consulting Co Ltd represents values of trust, innovation, and excellence in the field of clinical research and drug development. As a leading contract research organization, Tigermed is committed to providing high-quality services and solutions to pharmaceutical companies globally. With a strong focus on integrity and professionalism, the company aims to assist clients in achieving their clinical development goals efficiently. Moreover, Tigermed values collaboration, aiming to foster meaningful partnerships with its clients and professionals in the healthcare industry. Through cutting-edge technology and a customer-centric approach, Hangzhou Tigermed Consulting Co Ltd strives to be a reliable and strategic partner in advancing healthcare outcomes.

In which countries and regions is Hangzhou Tigermed Consulting Co primarily present?

Hangzhou Tigermed Consulting Co Ltd is primarily present in China, as it is a Chinese company. However, it also has a significant presence in other countries and regions. With its global expansion strategy, Hangzhou Tigermed Consulting Co Ltd has established branches and offices in numerous locations worldwide. These include the United States, Japan, South Korea, Europe, Australia, and Southeast Asia. This widespread presence allows Hangzhou Tigermed Consulting Co Ltd to offer its comprehensive range of pharmaceutical and clinical research services to clients internationally.

What significant milestones has the company Hangzhou Tigermed Consulting Co achieved?

Hangzhou Tigermed Consulting Co Ltd has achieved significant milestones in its history. As a leading contract research organization (CRO), the company has successfully established a global presence and expanded its service offerings. It has demonstrated its expertise in clinical research, regulatory affairs, and data management, serving clients across various therapeutic areas. Tigermed Consulting has also formed strategic partnerships with renowned pharmaceutical companies, positioning itself as a trusted partner in drug development and clinical trials. With its commitment to innovation and quality, Hangzhou Tigermed Consulting Co Ltd continues to make substantial advancements in the field of healthcare and contribute to improved patient outcomes.

What is the history and background of the company Hangzhou Tigermed Consulting Co?

Hangzhou Tigermed Consulting Co Ltd is a leading contract research organization (CRO) based in China. Founded in 2004, the company has rapidly grown to become one of the largest independent CROs in the country. Tigermed specializes in providing comprehensive clinical research and development services to pharmaceutical and biotech companies globally. With a strong focus on clinical trial management, regulatory affairs, and data management, Tigermed has established a solid reputation for delivering high-quality solutions to its clients. The company's commitment to excellence and extensive experience in the industry has enabled it to forge strong partnerships and contribute significantly to the advancement of healthcare research.

Who are the main competitors of Hangzhou Tigermed Consulting Co in the market?

Some of the main competitors of Hangzhou Tigermed Consulting Co Ltd in the market include PPD Inc., ICON plc, QuintilesIMS, PAREXEL International Corporation, and Wuxi AppTec.

In which industries is Hangzhou Tigermed Consulting Co primarily active?

Hangzhou Tigermed Consulting Co Ltd is primarily active in the pharmaceutical and biotech industries.

What is the business model of Hangzhou Tigermed Consulting Co?

The business model of Hangzhou Tigermed Consulting Co Ltd revolves around providing comprehensive and integrated clinical research services to support the development and marketing of pharmaceutical, biotechnological, and medical device products. As a leading Contract Research Organization (CRO) in China, Tigermed offers a wide range of services including project planning, clinical trial management, regulatory affairs, data management, statistical analysis, and quality assurance. By leveraging their expertise, experience, and strategic partnerships, Hangzhou Tigermed Consulting Co Ltd caters to the growing needs of domestic and international clients in the healthcare industry.

What is the P/E ratio of Hangzhou Tigermed Consulting Co 2024?

The Hangzhou Tigermed Consulting Co P/E ratio is 40.48.

What is the P/S ratio of Hangzhou Tigermed Consulting Co 2024?

The Hangzhou Tigermed Consulting Co P/S ratio is 7.33.

What is the Quality Investing of Hangzhou Tigermed Consulting Co?

The Quality Investing for Hangzhou Tigermed Consulting Co is 8/10.

What is the revenue of Hangzhou Tigermed Consulting Co 2024?

The expected Hangzhou Tigermed Consulting Co revenue is 7.55 B CNY.

How high is the profit of Hangzhou Tigermed Consulting Co 2024?

The expected Hangzhou Tigermed Consulting Co profit is 1.37 B CNY.

What is the business model of Hangzhou Tigermed Consulting Co

The Hangzhou Tigermed Consulting Co Ltd is a leading company in the field of clinical research, offering a wide range of services to its customers. The company was founded in 2004 and has its headquarters in Hangzhou, China. With offices in various cities in China, Europe, and the USA, the company now has over 800 employees worldwide. The business model of Tigermed Consulting is to support companies in developing and bringing new products to market. To this end, the company offers a wide range of services that span the entire product lifecycle. The company provides customers with support in the planning, execution, and evaluation of clinical studies, following applicable regulations and guidelines. The company specializes in clinical studies, regulatory affairs, medical devices, biostatistics, and medical writing services. Tigermed Consulting offers unique services to its customers, providing comprehensive solutions for their clinical studies, regulatory matters, and medical products. The company has experienced significant growth in recent years by offering a broad range of customizable services tailored to the specific needs of its customers. Overall, the business model of Tigermed Consulting aims to help its customers stay competitive and successfully bring their products to market. In a world driven by new technologies and innovations, it is important to leverage the expertise of companies like Tigermed Consulting to operate a successful and profitable business.

What is the Hangzhou Tigermed Consulting Co dividend?

Hangzhou Tigermed Consulting Co pays a dividend of 0.5 CNY distributed over payouts per year.

How often does Hangzhou Tigermed Consulting Co pay dividends?

The dividend cannot currently be calculated for Hangzhou Tigermed Consulting Co or the company does not pay out a dividend.

What is the Hangzhou Tigermed Consulting Co ISIN?

The ISIN of Hangzhou Tigermed Consulting Co is CNE100001KV8.

What is the Hangzhou Tigermed Consulting Co ticker?

The ticker of Hangzhou Tigermed Consulting Co is 300347.SZ.

How much dividend does Hangzhou Tigermed Consulting Co pay?

Over the past 12 months, Hangzhou Tigermed Consulting Co paid a dividend of 0.55 CNY . This corresponds to a dividend yield of about 0.86 %. For the coming 12 months, Hangzhou Tigermed Consulting Co is expected to pay a dividend of 0.6 CNY.

What is the dividend yield of Hangzhou Tigermed Consulting Co?

The current dividend yield of Hangzhou Tigermed Consulting Co is 0.86 %.

When does Hangzhou Tigermed Consulting Co pay dividends?

Hangzhou Tigermed Consulting Co pays a quarterly dividend. This is distributed in the months of July, June, August, August.

How secure is the dividend of Hangzhou Tigermed Consulting Co?

Hangzhou Tigermed Consulting Co paid dividends every year for the past 14 years.

What is the dividend of Hangzhou Tigermed Consulting Co?

For the upcoming 12 months, dividends amounting to 0.6 CNY are expected. This corresponds to a dividend yield of 0.93 %.

In which sector is Hangzhou Tigermed Consulting Co located?

Hangzhou Tigermed Consulting Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hangzhou Tigermed Consulting Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hangzhou Tigermed Consulting Co from 7/12/2024 amounting to 0.568 CNY, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did Hangzhou Tigermed Consulting Co pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Hangzhou Tigermed Consulting Co in the year 2023?

In the year 2023, Hangzhou Tigermed Consulting Co distributed 0.5 CNY as dividends.

In which currency does Hangzhou Tigermed Consulting Co pay out the dividend?

The dividends of Hangzhou Tigermed Consulting Co are distributed in CNY.

Scope 1 - Direct Emissions	124.06
Scope 2 - Indirect emissions from purchased energy	13,217.29
Scope 3 - Indirect emissions within the value chain	—
Total CO₂ emissions	13,341.35
CO₂ reduction strategy	✅
Coal energy	❌
Nuclear power	❌
Animal experiments	✅
Fur & Leather	—
Pesticides	—
Palm Oil	—
Tobacco	❌
Genetically modified organisms	❌
Climate concept	—
Sustainable forestry	—
Recycling regulations	❌
Environmentally friendly packaging	❌
Hazardous substances	❌
Fuel consumption and efficiency	✅
Water consumption and efficiency	✅

Percentage of female employees	82.565
Percentage of women in management	—
Percentage of Asian employees	—
Share of Asian management	—
Percentage of Hispanic/Latino employees	—
Hispano/Latino Management share	—
Percentage of Black employees	—
Black Management Share	—
Percentage of white employees	—
White Management Share	—
Adult content	❌
Alcohol	❌
Weapons	—
Firearms	❌
Gambling	❌
Military contracts	❌
Human rights concept	✅
Privacy concept	—
Occupational health and safety	✅
Catholic	✅

Environmental reporting	✅
Stakeholder Engagement	✅
Call Back Policies	❌
Antitrust law	❌

Hangzhou Tigermed Consulting Co Ticker	Hangzhou Tigermed Consulting Co FIGI
300347:CH	BBG002PKXG01
300347:CS	BBG002QKZ361
300347:C2	BBG00F13DR59

Own the gold standard ✨ in financial data & analytics

Price

Price

Ticker300347.SZ

ISINCNE100001KV8

Hangzhou Tigermed Consulting Co stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Hangzhou Tigermed Consulting Co Stock Price History

Hangzhou Tigermed Consulting Co Revenue, EBIT, Net Income CNE100001KV8 ·

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Hangzhou Tigermed Consulting Co Revenue, EBIT and net profit per share

Hangzhou Tigermed Consulting Co Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Hangzhou Tigermed Consulting Co stock margins CNE100001KV8 ·

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Hangzhou Tigermed Consulting Co Margin History

Hangzhou Tigermed Consulting Co Stock Sales Revenue, EBIT, Earnings per Share CNE100001KV8 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Hangzhou Tigermed Consulting Co Revenue, EBIT and net profit per share

Hangzhou Tigermed Consulting Co business model

Hangzhou Tigermed Consulting Co SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Hangzhou Tigermed Consulting Co Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Hangzhou Tigermed Consulting Co historical P/E ratio, EBIT multiple, and P/S ratio

Hangzhou Tigermed Consulting Co shares outstanding CNE100001KV8 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Hangzhou Tigermed Consulting Co stock splits

Hangzhou Tigermed Consulting Co dividend history and estimates CNE100001KV8 ·

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

Hangzhou Tigermed Consulting Co Dividend History

Hangzhou Tigermed Consulting Co dividend payout ratio CNE100001KV8 ·

Payout ratio

Ticker
300347.SZ

ISIN
CNE100001KV8